Combining Immunotoxin and Chemotherapy for Pleural Mesothelioma

Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Combination with Pemetrexed Disodium and Cisplatin in Patients with Unresectable Malignant Epithelial Pleural Mesothelioma (NCI-08-C-0026)

Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy

For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and toxicity of standard chemotherapy +/-pleurectomy/decortication followed by IMRT to the pleura in patients with malignant pleural mesothelioma.

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

For patients with malignant pleural mesothelioma that has grown despite treatment with standard chemotherapy, no treatment has yet proven beneficial. The purpose of this study is to find out what effects, both good and bad, that everolimus has on the cancer. Everolimus works by blocking a protein that helps the cancer grow. The goal of this clinical research study is to learn if the study drug everolimus can shrink or slow the growth of mesothelioma. The safety of this drug will also be studied. The patients’ physical state, changes in the size of the tumor, and laboratory findings taken during the study will help us decide if everolimus is safe and effective.

Bionomics testing new mesothelioma drug

Drug developer Bionomics Ltd plans to conduct a Phase II clinical trial of its leading compound, anti-cancer drug BNC105, on 60 Mesothelioma patients in Australia next year.

Medical Screening for Former Hanford Employees

According to the American Journal of Industrial Medicine, DOE construction workers have an increased risk of certain cancers. In fact, the most significant finding at Hanford was a very high rate of mesothelioma, a cancer of the protective lining that covers most of the body’s internal organs.

Carbon nanotubes could harm the lungs

Researchers from the North Carolina State University, The Hamner Institutes for Health Sciences, and the National Institute of Environmental Health Sciences used a mouse model to examine the effect of inhalation of multi-walled carbon nanotubes on the lungs.

Prometheus Launches ProOnc Dx Cancer Diagnostics

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSourceDx, ProOnc SquamousDx and ProOnc MesotheliomaDx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

Short Neoadjuvant Hemithoracic IMRT for MPM

Purpose: Malignant pleural mesotheliomas (MPMs) are tumours associated with asbestos exposure involving the tissue lining surrounding the lung. Radiation therapy (RT) dramatically reduces the risk of tumour recurrence within the irradiated area (>90%). But patients continue to succumb to MPMs due to the tumour spreading outside the chest cavity. This may be due to tumour cells inadvertently contaminating areas outside the chest cavity during surgery. The study will look at whether giving a short intense course of chest radiation just prior to surgery will sterilized these tumour cells and thus, avoid or reduce contamination of the areas outside the chest cavity. The investigators hypothesize that short neoadjuvant (pre-operative) hemithoracic RT, followed by immediate planned extrapleural pneumonectomy (EPP) (+/- adjuvant chemotherapy) will reduce the risk of intra-operative seeding and reduce the incidence of distant metastatic disease.

FirstHealth partners with Wake on study

PINEHURST – The FirstHealth of the Carolinas Clinical Trials Department has partnered with the Wake Forest School of Medicine to promote participation in a research study investigating the development and progression of asbestos-related lung diseases and cancers.

Hoosiers dying of asbestos exposure say law change is needed

Before she dies, Dorothy Kuykendall wants her day in court. The 76-year-old from Terre Haute was exposed to asbestos, a toxin that can lead to a deadly cancer called mesothelioma, more than three decades ago when she handled the material regularly as a worker at the city’s Glas-Col Apparatus Co.

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Despite the best surgical efforts, complete removal of mesothelioma is possible in approximately 30% of the patients. When surgical removal is complete, chemotherapy followed by radiation therapy is recommended as an effort to improve control over the cancer and survival. This combination of treatments is called TRIMODALITY therapy. Unfortunately, the chances for the tumor coming back after TRIMODALITY therapy remains high. When surgical removal is not complete or not possible, some patients may receive chemo and/or radiation therapy to achieve control over the cancer, but the chances of tumor to growth again remains high and the chances of long term survival remains low.